Bausch + Lomb Corporation (BLCO) Cash Flow Statement

The persistent gap between net income and operating cash flow suggests that non-cash charges, particularly D&A averaging over $100M per quarter, are masking underlying cash generation. However, the negative OCF/NI ratios (e.g., -15.3 in 2026Q2) indicate that earnings quality is poor, as losses are not fully explained by cash items. Investors should monitor whether this divergence narrows as the company approaches profitability.

The trajectory shows a clear improvement from the trough in early 2025, but FCF remains inconsistent, with negative quarters in 2025Q1, 2025Q2, and 2024Q4. The positive FCF in 2026Q2 is encouraging, yet the cumulative FCF over the last five quarters is still negative, indicating that the company has not yet achieved sustainable cash generation. The improvement appears driven by working capital releases and stable capex, but sustainability warrants further observation.

Capex as a percentage of revenue has been relatively stable, ranging from 5.0% to 9.7%, which is moderate for a medical instruments company. The consistency suggests that BLCO is investing primarily in maintenance and replacement rather than large-scale growth initiatives. However, the elevated capex in 2025Q1 (9.7% of revenue) may indicate a one-time investment, but the subsequent quarters show a return to normal levels. This implies that FCF generation is more dependent on operational efficiency than on capex discipline.

The large swings in working capital are a primary driver of quarterly cash flow variability. The negative working capital change in 2024Q4 (-$182M) likely reflects inventory build-up or receivable delays, while the positive changes in 2024Q3 and 2025Q3 suggest efficient collections or inventory reductions. This volatility complicates forecasting and suggests that management may be using working capital levers to manage cash flow. Investors should monitor whether these swings stabilize as the company grows.

Capital deployment is heavily skewed toward acquisitions and organic investment, with no dividends and minimal buybacks. The acquisition outflows, though sporadic, suggest a strategy of inorganic growth, which may explain the persistent net losses as integration costs weigh on earnings. The lack of shareholder returns may be a concern for income-focused investors, but it aligns with a company in a growth phase. The negative acquisition cash flows in 2024Q4 (-$91M) and 2026Q2 (-$15M) indicate ongoing M&A activity, which could strain liquidity if not managed carefully.

The cumulative gap between net income and operating cash flow is substantial, with OCF exceeding net income by over $1.4 billion. This suggests that non-cash charges, particularly D&A and possibly impairment charges, are inflating losses while cash operations remain viable. However, the negative net income indicates that the company is not yet profitable on a GAAP basis, and the cash flow may be supported by working capital management rather than core earnings. This divergence warrants close monitoring, as it may indicate that the company's cash generation is not sustainable if working capital tailwinds reverse.